Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Health Care

Nuclear

Orano Med

Julien Dodet

Thomas Priem

Julien Torgue

Nicolas Bozovic

Gwenaelle Nourry

Pascal Mirocha

Production and Operations

Quality Assurance and Control Team

Engineering and Technical Team

Research & Development

Administrative and Managerial

Human Resources Team

Leadership Team

Teams at Orano Med